Vertical: CNMBase Year: 2025
Market Size (2025)
$881.10M
Projected (2032)
$1.16B
CAGR (2022–2032)
4.7%
Key Players
12+
Market Overview
The global biosurfactant market was valued at USD 881.10 Million in 2025 and is projected to reach USD 1,160.69 Million by 2032, expanding at a CAGR of 3.90% during 2026–2032. The market has grown steadily from USD 735.80 Million in 2022, and is expected to add USD 279.59 Million in absolute value between 2025 and 2032. Biosurfactants are surface-active molecules produced by microbial fermentation, principally glycolipids such as sophorolipids and rhamnolipids, and lipopeptides such as surfactin. They are moving from niche, high-cost specialty ingredients into mainstream formulations as detergent, personal care and agrochemical manufacturers look for readily biodegradable, low-toxicity and bio-based alternatives to petrochemical and palm-derived surfactants.
Commercial momentum has strengthened since 2022. Large chemical producers have commissioned the first industrial-scale rhamnolipid capacity, sophorolipid producers have attracted strategic investment from global surfactant majors, and consumer goods companies have begun to place biosurfactants on the front label of mass-market dishwashing, laundry and personal care brands. Growth through 2032 will be shaped by the pace at which fermentation costs fall, by regulation that favours biodegradable and bio-based ingredients, and by demand from Asia Pacific, where both manufacturing capacity and end-use consumption are expanding fastest.
Key Findings
By Product Type: Glycolipids (Sophorolipids & Rhamnolipids) is both the largest and the fastest-growing segment, accounting for 65.00% of the market in 2025 (USD 572.71 Million) and growing at a CAGR of 4.31%.
By Application: Household Detergents is the largest application, with a 35.00% share in 2025 (USD 308.38 Million). Personal Care is the fastest-growing application, at a CAGR of 4.87%.
By Region: Europe is the leading region, with a 38.00% share in 2025 (USD 334.82 Million). Middle East & Africa is the fastest-growing region, at a CAGR of 5.23%. Asia Pacific, growing at 4.76%, adds the largest absolute value among regions (USD 115.02 Million between 2025 and 2032).
By Country: The U.S. is the largest country market, valued at USD 158.95 Million in 2025. India is the fastest-growing country, at a CAGR of 7.11%.
Segmentation Summary
The market is analysed by product type and application, across five regions and their constituent countries. Among product types, Glycolipids (Sophorolipids & Rhamnolipids) are projected to rise from USD 572.71 Million in 2025 to USD 775.48 Million by 2032, registering a CAGR of 4.31% during 2026–2032. Their lead rests on high-titre sophorolipid fermentation and newly commissioned industrial rhamnolipid capacity. Lipopeptides & Others are expected to grow from USD 308.38 Million in 2025 to USD 385.21 Million by 2032, registering a CAGR of 3.11% during 2026–2032, supported by surfactin in cosmetics and Bacillus-derived lipopeptides in agriculture and oilfield uses.
By application, Household Detergents (USD 308.38 Million in 2025) remains the volume anchor, driven by eco-label dishwashing and laundry products. Personal Care and Oilfield & Others are joint second-largest at USD 220.27 Million each in 2025. Personal Care grows fastest (4.87%), whereas Oilfield & Others grows slowest (2.69%). Agriculture, valued at USD 132.16 Million in 2025, is expected to expand at 4.56%, supported by biological crop protection and adjuvant demand.
Competitive Landscape Summary
The competitive landscape is moderately consolidated at the top and fragmented below. Evonik Industries leads in rhamnolipids following the 2024 start-up of its industrial-scale plant in Slovakia. Locus Fermentation Solutions, the Sasol–Holiferm partnership and Syensqo are prominent in sophorolipids. BASF, Kaneka, Saraya and Stepan Company bring biosurfactants into broader chemical and consumer portfolios, and specialists such as Allied Carbon Solutions, AGAE Technologies and Jeneil Biotech serve focused molecule and application niches. Competition centres on cost per kilogram, fermentation scale, regulatory dossiers and co-development agreements with consumer goods and agrochemical customers. Strategic partnerships, rather than outright acquisitions, have been the dominant route to scale since 2022.
Challenges and Opportunities
The principal challenge is cost. Biosurfactants generally remain several times more expensive per kilogram than commodity anionic and non-ionic surfactants such as linear alkylbenzene sulfonate (LAS) and fatty alcohol ethoxylates. This limits penetration in price-sensitive mass-market detergents and oilfield chemicals. Further constraints are limited large-scale fermentation and downstream purification capacity, batch-to-batch consistency, and the cost and time of chemical registration in multiple jurisdictions. On the opportunity side, regulatory pressure on persistence and aquatic toxicity, corporate net-zero and bio-based content targets, and the growth of biological crop inputs create a widening addressable market. Next-generation feedstocks (waste oils, food-industry side streams and lignocellulosic sugars) and precision-fermentation strain engineering offer a credible path to lower costs.
Future Outlook
Between 2026 and 2032 the market is expected to grow from USD 922.55 Million to USD 1,160.69 Million. Year-on-year growth moderates gradually as the base enlarges and early-adopter demand matures. Glycolipids will continue to gain share, with their portion of the market rising from 65.00% in 2025 to 66.81% in 2032. Personal Care and Agriculture will gain share at the expense of Oilfield & Others. Geographically, Asia Pacific is projected to close most of the gap with Europe, reaching USD 405.78 Million by 2032 against Europe's USD 418.80 Million. Success will depend on cost reduction through scale and feedstock flexibility, on application-specific product design, and on long-term offtake partnerships with brand owners.
The Biosurfactant Market market is projected to grow at a CAGR of 4.7% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Biosurfactants are amphiphilic, surface-active compounds synthesised by microorganisms (bacteria, yeasts and fungi) through fermentation. Each molecule combines a hydrophilic moiety, such as a sugar, amino acid or peptide, with a hydrophobic fatty-acid or hydroxy-fatty-acid tail. Biosurfactants lower surface and interfacial tension, form micelles at low critical micelle concentrations, and provide emulsifying, wetting, foaming, dispersing and solubilising functions comparable to synthetic surfactants. They are typically readily biodegradable and of low aquatic toxicity. Commercially important classes include sophorolipids (produced mainly by the yeast Starmerella bombicola), rhamnolipids (produced by Pseudomonas species and engineered non-pathogenic hosts), mannosylerythritol lipids (MELs), and cyclic lipopeptides such as surfactin, iturin and fengycin produced by Bacillus species.
Included in the scope of this study:
Microbially produced glycolipid biosurfactants, comprising sophorolipids and rhamnolipids, sold as concentrates, solutions or formulated actives.
Lipopeptide biosurfactants (for example surfactin and other Bacillus-derived lipopeptides) and other microbial biosurfactant classes (for example MELs, cellobiose lipids, trehalolipids and polymeric bioemulsifiers).
Biosurfactants used in household detergents, personal care, agriculture, oilfield and other industrial applications such as environmental remediation, food processing and industrial cleaning.
Market value at the level of the biosurfactant ingredient sold by producers, measured in USD Million.
Excluded from the scope of this study:
Bio-based surfactants made by chemical synthesis from renewable feedstocks, such as alkyl polyglucosides (APGs), sugar esters, sorbitan esters, methyl ester sulfonates and glucamides, which are not microbially produced.
Conventional petrochemical and oleochemical surfactants.
Value of finished consumer or industrial products (for example a complete detergent or shampoo) in which biosurfactants are only an ingredient.
Live microbial inoculants sold for their biological activity rather than as surfactant ingredients.
Research Objectives
To estimate the size of the global biosurfactant market for 2022–2025 and forecast it for 2026–2032 in USD Million.
To analyse the market by product type, distinguishing glycolipids (sophorolipids and rhamnolipids) from lipopeptides and other biosurfactant classes, and to identify the relative growth of each.
To quantify demand across household detergents, personal care, agriculture and oilfield and other applications, and to assess substitution of conventional surfactants in each.
To assess regional and country-level demand patterns across North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
To identify and evaluate the drivers, restraints, opportunities, trends and challenges affecting fermentation-based surfactant production and adoption.
To examine the regulatory environment, including chemical registration, biodegradability and eco-label requirements, that shapes market access for biosurfactants.
To profile the competitive landscape, positioning of leading producers and their strategic developments since 2022.
To analyse the value chain from fermentation feedstocks to end users and identify points of cost and margin concentration.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage research process combining extensive secondary research, primary validation with industry participants, and quantitative modelling. The process began with market definition and segmentation design. Data was then collected from public and proprietary sources on biosurfactant production capacity, pricing, trade and end-use consumption, and the market was sized for the historic period using complementary top-down and bottom-up approaches. Estimates were triangulated and validated through discussions with producers, formulators and end users, then projected over the forecast horizon using a driver-based model. Each stage included quality checks to ensure internal consistency across segments, regions and countries.
Stage 1 – Scoping: definition of biosurfactant classes, applications and geographic coverage.
Stage 2 – Secondary research: collection of industry, regulatory, company and trade data.
Stage 3 – Market modelling: top-down and bottom-up estimation for 2022–2025.
Stage 4 – Primary validation: interviews with supply-side and demand-side participants.
Stage 5 – Forecasting and triangulation: driver-based projection for 2026–2032 and reconciliation of estimates.
Stage 6 – Review and reporting: consistency checks and analysis.
Secondary Research
Secondary research established the baseline understanding of the market. The main source categories were:
Industry associations: publications and statistics from surfactant and detergent associations such as the European Committee of Organic Surfactants and their Intermediates (CESIO), the International Association for Soaps, Detergents and Maintenance Products (A.I.S.E.), the American Cleaning Institute (ACI), the Japan Soap and Detergent Association, and industrial biotechnology bodies such as EuropaBio and the Biotechnology Innovation Organization.
Government and regulatory bodies: chemical registration databases and guidance from the European Chemicals Agency (ECHA), the U.S. Environmental Protection Agency (TSCA inventory, Safer Choice and biopesticide registrations), the USDA BioPreferred programme, the European Commission, China's Ministry of Ecology and Environment, and India's Department of Biotechnology.
Company filings: annual reports, investor presentations, sustainability reports and press releases of biosurfactant producers, surfactant majors and consumer goods companies.
Trade journals and scientific literature: specialist chemical, home and personal care and agrochemical trade press, and peer-reviewed literature on fermentation titres, yields and downstream processing of sophorolipids, rhamnolipids and lipopeptides.
Trade and patent data: customs and trade statistics for surface-active agents, and patent databases to track technology and capacity developments.
Paid databases: subscription company, financial and market intelligence databases used to cross-check company revenues, capacities and transactions.
Primary Research
Primary research validated secondary findings, filled data gaps and gathered qualitative insight into market dynamics. Structured and semi-structured interviews were conducted by telephone, video conference and e-mail.
Supply-side respondents: senior executives, business development and product managers, and R&D and process engineering staff at biosurfactant producers, surfactant manufacturers, contract fermentation organisations and distributors.
Demand-side respondents: formulation chemists, procurement and sustainability managers at household care, personal care and cosmetics companies; agrochemical and biologicals formulators; and oilfield chemical service companies.
Other respondents: academic researchers in industrial biotechnology, regulatory consultants and industry association representatives.
Objectives: to validate market size and segment splits, understand pricing and cost trends, assess capacity additions and adoption barriers, and gauge the outlook for each application and region.
Market Size Estimation
Top-down approach: The overall surfactant market was used as the starting point. The share attributable to biosurfactants was estimated for each application and region from adoption rates, product launch tracking and interview feedback. These shares were applied to application-level surfactant consumption to derive biosurfactant demand, which was then allocated to product types.
Bottom-up approach: Revenues and production volumes of leading biosurfactant producers were estimated from company disclosures, announced fermentation capacities, utilisation assumptions and average selling prices. These were aggregated by product type and region, and an allowance was added for smaller and regional producers.
Data triangulation: The two approaches were reconciled, and differences were investigated through further secondary research and primary interviews. The final estimates were chosen to be consistent across product type, application, region and country, so that every segmentation adds up to the same market total in every year.
Forecasting Methodology
Forecasts for 2026–2032 were developed with a driver-based model that projects demand for each application-region combination and then aggregates it. Historic growth trends were adjusted for the expected impact of quantified and qualitative factors, including:
Growth of underlying end-use markets (household care, personal care, crop protection and oilfield chemicals).
Expected substitution rates of conventional surfactants by biosurfactants, by application and region.
Announced and expected fermentation capacity additions, and the resulting effect on price and availability.
Price trajectory of biosurfactants relative to conventional surfactants, including feedstock cost trends.
Regulatory developments affecting biodegradability, eco-labelling, chemical registration and biological crop inputs.
Macroeconomic indicators such as GDP, consumer spending, agricultural output and oil and gas activity.
Assumptions and Limitations
Market values are expressed in nominal USD. Local-currency revenues are converted at average annual exchange rates for each historic year, and constant rates are assumed for the forecast period.
The forecast assumes no major disruption to global trade, fermentation feedstock supply (sugars and vegetable oils) or industrial energy availability.
Announced capacity expansions are assumed to come on stream broadly as communicated by the companies concerned.
Regulatory frameworks are assumed to evolve as currently proposed, without sudden restrictions on microbial production hosts.
Many biosurfactant producers are privately held and do not disclose segment revenues, so company-level estimates carry a higher margin of uncertainty.
Classification of products as biosurfactants follows the definition in Section 2.1. Products marketed as 'bio-based' but chemically synthesised are excluded, which may cause differences from other published estimates.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global biosurfactant market is moderately consolidated at the top and fragmented below. A small number of companies with industrial-scale fermentation capacity or strong surfactant market access account for a significant portion of commercial volumes. These include Evonik in rhamnolipids, the Sasol–Holiferm partnership and Locus Fermentation Solutions in sophorolipids, and Syensqo in personal care sophorolipids. Around them sits a broad base of specialist producers, university spin-outs and regional players, many still at pilot or early commercial scale.
Competition is driven less by price than by the ability to supply reliable volumes at falling cost, to provide regulatory dossiers and sustainability data, and to support customers' reformulation. Partnerships are the dominant competitive tool. Large surfactant and chemical companies have chosen to access fermentation know-how through offtake, distribution and equity arrangements, as with Sasol and Holiferm, Dow and Locus, and BASF with Allied Carbon Solutions and Holiferm. Brand owners such as Unilever have entered long-term co-development and supply agreements with producers. Venture and public funding continues to bring new entrants focused on waste-derived feedstocks and novel molecules, while some diversified players are rationalising their fermentation footprints.
Key Player Positioning
Leaders: Evonik Industries, Locus Fermentation Solutions, Sasol (with Holiferm) and Syensqo. These companies combine commercial-scale supply or broad market access, established brands and partnerships with major formulators.
Challengers: Holiferm, BASF, Saraya, Kaneka and Stepan Company. These companies have proven technology, recognised brands or strong parent-company resources, but their biosurfactant scale is smaller, their focus is narrower or their strategy is in transition.
Niche players: Allied Carbon Solutions, AGAE Technologies and Jeneil Biotech, together with emerging start-ups such as Dispersa and AmphiStar. These companies focus on specific molecules, feedstocks or applications such as agriculture, remediation and industrial cleaning.
Evonik Industries AG
Evonik is a German specialty chemicals group whose biosurfactants are produced at its Evonik Fermas site in Slovenská Ľupča, Slovakia. In January 2022 it announced a triple-digit million-euro investment in the world's first industrial-scale rhamnolipid plant, together with a long-term supply agreement with Unilever. Production began in January 2024 and the plant was inaugurated in May 2024. Its strategy combines first-mover industrial scale, a European sugar-based feedstock that avoids tropical oils, an anchor customer in home care, and the REWOFERM and RHEANCE brands to extend into cleaning and personal care. Biosurfactants form part of the company's 'Next Generation Solutions' sustainability portfolio.
Locus Fermentation Solutions
Locus Fermentation Solutions is a privately held U.S. biotechnology company founded in 2013, holding more than 1,300 patents. Its Locus Performance Ingredients unit serves home and personal care. Dow signed an exclusive agreement in January 2022 to sell Locus sophorolipids globally in home and personal care. Locus secured a USD 117 million IP-backed loan in 2023, opened two new manufacturing facilities in Solon that year, and in October 2024 received EPA approval for commercial-volume production under an expanded TSCA registration. It raised a further USD 20 million in December 2025 and reported fourfold year-on-year capacity growth in mid-2026. Its strategy is to be the leading U.S. domestic glycolipid producer, serving oil and gas, mining, agriculture and consumer products.
Sasol Limited
Sasol is an integrated energy and chemicals group whose biosurfactant activity sits within its international chemicals business. In March 2022 it agreed to take most of the sophorolipid output of Holiferm's UK plant and to fund Holiferm's R&D. In January 2023 the collaboration was extended to rhamnolipids and mannosylerythritol lipids. In October 2023 Sasol launched the CARINEX and LIVINEX biosurfactant brands. Its strategy is asset-light in fermentation: Sasol owns the brands, formulation support and global distribution, while relying on Holiferm's technology and capacity.
Syensqo SA
Syensqo is a specialty chemicals group created from the separation of Solvay's specialty businesses in December 2023. Its Mirasoft SL sophorolipid range, launched in June 2022, is made by fermenting rapeseed oil and sugar and is positioned as a mild, bio-based alternative to fossil-derived and ethoxylated surfactants in shampoos, body washes and facial cleansers. The range sits within the Performance & Care segment, for which Syensqo launched a strategic review in May 2026 as part of its plan to become a pure-play specialty materials company.
Holiferm Limited
Holiferm is a University of Manchester spin-out, founded in 2018, that produces sophorolipids from rapeseed oil and glucose using a patented continuous fermentation and gravity-separation process. It opened its first commercial plant at Wallasey in February 2023 with about 1,100 tonnes per year of capacity. In December 2023 it raised GBP 18.5 million to expand capacity to 3,500 tonnes per year, with a longer-term target of 15,000 tonnes. Its strategy combines its own HoliSurf brand, sold through distributors, with partnerships with surfactant majors, notably Sasol for offtake and BASF for technology cooperation.
BASF SE
BASF participates in microbial biosurfactants mainly through partnerships rather than its own fermentation plants. In 2021 it became the largest shareholder in Allied Carbon Solutions and signed a technology cooperation agreement with Holiferm covering glycolipids other than sophorolipids. Its BioToLife sophorolipid targets personal care in Asia. BASF's wider bio-based surfactant investments focus on chemically produced alkyl polyglucosides, which fall outside the scope of this study. Its Care Chemicals division aims to raise the share of renewable feedstocks in its portfolio.
Stepan Company
Stepan is a major U.S. surfactant producer that entered fermentation-derived biosurfactants by acquiring the NatSurFact rhamnolipid business from Logos Technologies in 2020 and a fermentation plant in Lake Providence, Louisiana, in 2021. The rhamnolipid portfolio targets agriculture, oilfield, personal care, household and industrial and institutional markets. In December 2025 Stepan sold its Lake Providence manufacturing assets as part of a footprint optimisation programme. This indicates a more selective, asset-light approach to biosurfactants within its broader surfactant business.
Kaneka Corporation
Kaneka is a diversified Japanese chemicals company that produces high-purity surfactin, a cyclic lipopeptide made by Bacillus subtilis fermentation, mainly for cosmetics. KANEKA Surfactin is effective at very low concentrations, is COSMOS and Ecocert certified, and is registered under REACH, TSCA and IECSC. It is distributed internationally through partners such as Brenntag Specialties in the U.S. Kaneka's strategy is to position surfactin as a niche, high-value ingredient for emulsification and cleansing, supported by formulation and OEM services.
Saraya Co., Ltd.
Saraya is a privately held Japanese hygiene and detergent company and a pioneer of commercial sophorolipids. Its research began in 1997 and stable production of SOFORO was reached in 2001. The company is vertically integrated, using SOFORO in its own consumer and professional cleaning brands while also selling it as an ingredient. Since 2022 it has promoted SOFORO internationally, for example at the AOCS Annual Meeting in 2025 and at Expo 2025 Osaka, Kansai. It is diversifying applications into cosmetics, food hygiene, medical cleaning and life-science uses such as cell cryopreservation.
Allied Carbon Solutions Co., Ltd.
Allied Carbon Solutions, founded in 2006, develops and mass-produces sophorolipids by yeast fermentation of plant oils, including non-edible mahua oil, and plant-derived sugars. BASF has been its largest shareholder since 2021. In October 2024 it raised JPY 550 million in a Series C round to fund customer co-development, production expansion in Japan and overseas, and new sales channels in Asia, the Middle East and Europe. It targets personal care, home care, agriculture and livestock applications.
AGAE Technologies, LLC
AGAE Technologies, founded in 2010, is a rhamnolipid specialist focused on low-cost, high-yield fermentation and purification. In 2022 it reported successful operation of its pilot plants and filed a provisional patent on foam control. In February 2025 it began industrial production at a full-scale manufacturing complex in Asia, operated with partners, with capacity of more than 1,000 tonnes per year. AGAE targets household cleaners, cosmetics, degreasers, bioremediation, oilfield and agricultural applications.
Jeneil Biotech, Inc.
Jeneil Biotech is a privately held fermentation company and one of the earliest commercial rhamnolipid producers. Its affiliate Jeneil Biosurfactant Company holds the EPA registration for ZONIX, a rhamnolipid-based biofungicide registered in 2004, and won a U.S. EPA Presidential Green Chemistry Challenge award for its rhamnolipid technology. The company focuses on agriculture, bioremediation, household and personal care, and antimicrobial applications. Its biosurfactant activity is a niche business alongside its core flavour and fermentation operations.
Threat of New Entrants: Medium
Venture-backed start-ups and contract fermentation capacity have lowered the cost of entering at pilot scale.
Scaling to industrial volumes requires heavy capital investment, proprietary strains and multi-jurisdiction registrations, which limits credible entrants.
Incumbents' long-term supply agreements with brand owners raise switching barriers for customers.
Bargaining Power of Suppliers: Low
Key inputs (sugars, vegetable oils, nutrients) are widely traded commodities with many suppliers.
Feedstock flexibility, including waste oils and side streams, further reduces dependence on any single supplier.
Specialised strain and equipment providers have some leverage, but this is limited by in-house development.
Bargaining Power of Buyers: High
Large consumer goods and agrochemical companies buy in significant volumes and can always revert to conventional surfactants.
Buyers demand cost-down roadmaps, dual sourcing and extensive technical and regulatory documentation.
Smaller premium brands have less leverage but represent limited volumes.
Threat of Substitutes: High
Chemically synthesised bio-based surfactants (APGs, sugar esters, glucamides, amino-acid surfactants) offer renewable content at lower cost.
Conventional petrochemical and oleochemical surfactants remain cheaper and well understood by formulators.
Biosurfactants' differentiated functionality (mildness, bioactivity, ready biodegradability) only partly offsets this threat.
Intensity of Competitive Rivalry: Medium
The market is growing, which moderates rivalry, and many producers focus on different molecule classes or applications.
Competition is intensifying in sophorolipids and rhamnolipids for home and personal care as new capacity comes online.
Rivalry centres on cost, scale, performance data and partnerships rather than on price wars.
Threat of New Entrants: Medium; Low pilot-scale barriers; high industrial-scale and registration barriers.
Bargaining Power of Suppliers: Low; Commodity feedstocks with many sources.
Bargaining Power of Buyers: High; Concentrated, large buyers with ready conventional alternatives.
Threat of Substitutes: High; Lower-cost synthetic bio-based and conventional surfactants.
Intensity of Competitive Rivalry: Medium; Growing market; rivalry rising in glycolipids.
Market estimates by geography (2032)
InsightEurope leads with $418.80M by 2032, while Middle East & Africa is projected to grow fastest at a 6.0% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $163.20M | $211.07M | $250.48M | 4.4% | 22% |
| Europe | $285.21M | $361.48M | $418.80M | 3.9% | 36% |
| Asia Pacific | $236.63M | $323.75M | $405.78M | 5.5% | 35% |
| Latin America | $29.56M | $38.66M | $47.57M | 4.9% | 4% |
| Middle East & Africa | $21.19M | $29.71M | $38.07M | 6.0% | 3% |
| Total | $735.80M | $964.68M | $1.16B | 4.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$1.16B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Glycolipids (Sophorolipids & Rhamnolipids) | $775.48M | 5.1% | 67% |
| Lipopeptides & Others | $385.21M | 3.9% | 33% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Biosurfactant Market covering market dynamics, competitive landscape, and strategic outlook.
The Biosurfactant Market market is projected to reach $1.16B by 2032, growing at 4.7% CAGR. The Glycolipids (Sophorolipids & Rhamnolipids) segment holds the largest share.
The biosurfactant market sits at the intersection of industrial biotechnology, specialty chemicals and consumer sustainability. Its dynamics are driven by tightening expectations on biodegradability and aquatic toxicity, brand-owner commitments to renewable carbon, and steady improvements in fermentation economics. Persistent cost premiums over conventional surfactants and limited production capacity act as counterweights. This chapter reviews the macro- and micro-level factors that influence growth, followed by a detailed discussion of drivers, restraints, opportunities, trends and challenges.
Regulatory Pressure for Biodegradable and Low-Toxicity Surfactants
Surfactants are among the highest-volume chemicals discharged to wastewater, and regulators are steadily raising the bar on their environmental profile. In the European Union, Regulation (EU) 2026/405 on detergents and surfactants was published in March 2026 and will replace Regulation (EC) No 648/2004 from September 2029. It retains the requirement for surfactants to be ultimately biodegradable and adds digital labelling, a digital product passport and a dedicated framework for detergents containing micro-organisms. EU Ecolabel criteria for detergents and cosmetics set limits on aquatic toxicity and anaerobic non-biodegradability that favour readily biodegradable surfactants. In the United States, the EPA Safer Choice programme and the USDA BioPreferred programme give formulators a commercial reason to use ingredients with strong environmental and bio-based credentials. Because sophorolipids, rhamnolipids and surfactin typically pass OECD 301 ready biodegradability tests and show low ecotoxicity, they let formulators meet these criteria without compromising performance. Regulatory momentum is therefore one of the most durable growth drivers, particularly in Europe and in export-oriented manufacturing hubs in Asia.
Brand-Owner Sustainability Commitments and Renewable Carbon Targets
Leading consumer goods companies have committed to removing fossil carbon from their cleaning and personal care formulations, and surfactants are typically the largest single contributor to the carbon footprint of a detergent's ingredients. Unilever, for example, has set a target to replace fossil-fuel-derived carbon in its cleaning and laundry formulations with renewable or recycled carbon by 2030, and has co-developed rhamnolipids with Evonik for use in dishwashing liquids. Biosurfactants are attractive in this context because they are fully bio-based, can be produced from non-palm feedstocks, and support front-of-pack 'plant-based' and 'naturally derived' claims under ISO 16128-style indices. These commitments translate into multi-year offtake agreements and co-development projects. Such agreements reduce demand risk for producers and help finance new fermentation capacity, making brand-owner pull a central driver through 2032.
Scale-Up of Industrial Fermentation Capacity
For most of the past two decades the main barrier to adoption was the lack of reliable, large-scale supply. That is changing. Evonik commissioned the world's first industrial-scale rhamnolipid plant in Slovenská Ľupča, Slovakia, in 2024. Sophorolipid producers in Europe, North America and Asia have expanded fermentation volumes, and contract development and manufacturing organisations have increasingly made precision-fermentation capacity available to start-ups. Larger fermenters, higher titres from engineered strains, continuous or semi-continuous processing, and better downstream separation are reducing unit costs and improving batch consistency. Greater availability, in turn, gives formulators the supply security they need to reformulate high-volume brands. This creates a positive feedback loop between capacity investment and demand.
Demand for Mild, Natural and Multifunctional Personal Care Ingredients
Consumers increasingly favour mild, sulfate-free and naturally derived personal care products. Biosurfactants fit this demand well: sophorolipids offer gentle cleansing with low irritation potential, MELs and surfactin offer skin-conditioning and barrier-supporting properties, and several biosurfactants show antimicrobial or deodorising activity that allows multifunctional claims. These functional benefits justify premium pricing in skin care, hair care and cosmetics, where the cost of the surfactant is a small fraction of the retail price. Personal Care is therefore the fastest-growing application, rising from USD 220.27 Million in 2025 to USD 309.72 Million in 2032. Growth is strongest in Asia Pacific, where Japanese and Korean cosmetics brands were early adopters of biosurfactant-based ingredients.
Biological Crop Protection, Biostimulants and Adjuvants
The rapid growth of biological crop inputs opens a high-value avenue for biosurfactants. Rhamnolipids and lipopeptides have demonstrated antifungal and zoosporicidal activity. Rhamnolipid-based biofungicides have been registered in the United States, and Bacillus lipopeptides underpin many commercial biocontrol products. Biosurfactants can also serve as biodegradable adjuvants and wetting agents, improving the spread and uptake of crop protection products and biostimulants, and supporting soil remediation. Supportive policies, such as the EU's target to reduce chemical pesticide use and its framework for biostimulants, as well as rapid adoption of biologicals in Brazil and India, position Agriculture as a structural growth segment. It is projected to expand at a CAGR of 4.56% globally.
Waste and Side-Stream Feedstocks
Producing biosurfactants from low-cost feedstocks, such as used cooking oil, food-processing by-products, crude glycerol from biodiesel and lignocellulosic sugars, can reduce costs and strengthen circular-economy credentials. Projects pairing fermentation with agro-industrial residues are gaining public research funding in Europe and Asia. Commercial adoption would lower the cost gap with conventional surfactants and support lower carbon footprints.
Expansion in Emerging Markets and Industrial Cleaning
Rising incomes, urbanisation and the formalisation of home care and personal care markets in India, Southeast Asia, Latin America and the Gulf create new demand pools for premium and eco-labelled products. Industrial and institutional cleaning, food-processing hygiene and environmental remediation offer further applications. In these uses, biosurfactants' low toxicity and biodegradability are especially valuable, as with oil-spill dispersants and contaminated soil washing.
High Production Costs and Price Premium
Biosurfactants remain substantially more expensive to produce than petrochemical or oleochemical surfactants. Fermentation titres for several classes, especially rhamnolipids and lipopeptides, are still modest compared with the productivity of conventional chemical processes. Downstream recovery and purification can account for a large share of total cost, and plants operate at a fraction of the scale of commodity surfactant units. As a result, biosurfactants typically sell at a multiple of the price of LAS or alcohol ethoxylates. In price-sensitive segments such as mass-market laundry powders, emerging-market detergents and oilfield chemicals, this premium restricts usage to low inclusion levels or premium product lines.
Limited Production Capacity and Supply Concentration
Global biosurfactant capacity is concentrated among a small number of producers, and several fermentation technologies are proprietary. Large formulators are reluctant to commit a global brand to an ingredient with only one or two qualified suppliers, owing to supply-continuity and price-negotiation risks. New capacity requires significant capital, long lead times and regulatory registration of each new site and product. This slows the pace at which supply can respond to demand.
Regulatory and Registration Complexity
Although biosurfactants are generally benign, they are often new substances that require registration under chemical control laws such as EU REACH, U.S. TSCA, China's new chemical substance notification and Korea's K-REACH. Agricultural uses may also require pesticide or fertilising-product approvals. The cost and duration of building dossiers for multiple jurisdictions are significant for smaller producers and can delay market entry by several years.
Challenge: Performance Parity and Formulation Compatibility
Biosurfactants do not always behave like the conventional surfactants they replace. Foam profile, hard-water tolerance, viscosity building and compatibility with enzymes, preservatives and fragrances can all differ. Formulators therefore need time and technical support to reformulate, and blends with conventional surfactants remain common. Building application laboratories and formulation guidance is now a competitive requirement.
Challenge: Substantiating Sustainability Claims
Regulators in Europe and elsewhere are cracking down on vague environmental claims. Producers must therefore support claims of bio-based content, biodegradability and carbon reduction with verified life-cycle assessments and certifications. Credible data on feedstock sourcing, energy use in fermentation and end-of-life behaviour are becoming prerequisites for supply contracts with major brand owners.
Trend: Strategic Partnerships between Fermentation Specialists and Surfactant Majors
Rather than build fermentation competencies from scratch, many established surfactant and specialty chemical companies are partnering with or investing in fermentation specialists. Under these arrangements, the specialist contributes strain and process know-how, and the major contributes formulation expertise, regulatory capability and global customer access. These alliances are accelerating commercialisation and are likely to culminate in further equity investments and acquisitions.
Trend: Engineered Strains and Precision Fermentation
Advances in synthetic biology let producers move rhamnolipid production away from opportunistically pathogenic Pseudomonas aeruginosa towards safe production hosts. They also allow producers to tailor congener profiles for specific functions and to raise titres. Tailored molecules, such as mono- versus di-rhamnolipids, acidic versus lactonic sophorolipids, and specific MEL variants, enable application-specific grades with differentiated performance.
The biosurfactant value chain runs from agricultural and oleochemical feedstocks through fermentation and downstream processing to formulators and end users. Value is concentrated in the fermentation and purification stages, where proprietary strains, process know-how and regulatory dossiers create barriers to entry.
Raw materials and inputs. Feedstock costs account for a significant share of the cost of goods. Producers are diversifying away from palm-based oils towards regionally available and certified feedstocks. Strains and media optimisation largely determine titre and yield.
Manufacturing. Fermentation is capital-intensive and scale-sensitive. Productivity (grams per litre per hour), oxygen transfer and foam control are the main technical constraints, the last being particularly acute for rhamnolipids and surfactin.
Distribution and channels. Biosurfactants are sold largely business-to-business. Technical service and joint formulation work are integral to the sale, and distributors with home and personal care application labs are important for reaching small and medium-sized brands.
End users. Brand owners capture most of the consumer value, and use biosurfactants to differentiate on sustainability and mildness. Long-term offtake agreements increasingly link end users directly to producers.
Biosurfactants are regulated at three levels: as chemical substances, through chemical registration laws; by end use, through detergent, cosmetic and agricultural input rules; and through voluntary eco-labels and procurement programmes that reward biodegradable and bio-based ingredients. The key instruments in the main regions are summarised below.
Europe
REACH – Regulation (EC) No 1907/2006: biosurfactants manufactured or imported at one tonne or more per year must be registered with the European Chemicals Agency, with data requirements rising by tonnage band. In April 2026 the Commission confirmed it would not table a full REACH revision and would instead pursue targeted simplification of its annexes.
Detergents and Surfactants – Regulation (EU) 2026/405: published in the Official Journal in March 2026, it replaces Regulation (EC) No 648/2004, with most provisions applying from September 2029. It keeps the ultimate-biodegradability requirement for surfactants and introduces rules for detergents with intentionally added micro-organisms, a digital product passport and digital labelling.
EU Ecolabel criteria for detergents and cleaning products: Commission Decisions (EU) 2017/1214 to 2017/1219, extended to 31 December 2026 and currently under revision. They set aquatic toxicity and biodegradability limits based on the Detergent Ingredient Database (DID List).
Cosmetic Products – Regulation (EC) No 1223/2009: governs safety assessment, notification through the Cosmetic Products Notification Portal and INCI labelling of biosurfactants in personal care products.
Fertilising Products – Regulation (EU) 2019/1009: applicable since July 2022, it created a CE-marked category for plant biostimulants. This provides a route to market for biosurfactant-based biostimulants and adjuvants, supported by the EN 17700 series of harmonised test methods.
North America
Toxic Substances Control Act (TSCA): new biosurfactants require a Premanufacture Notice to the U.S. EPA. Genetically engineered production microorganisms fall under the biotechnology rules at 40 CFR Part 725.
FIFRA biopesticide registration: rhamnolipid biosurfactant is registered with the EPA as a biochemical pesticide active ingredient (the ZONIX biofungicide, registered in 2004), with an exemption from the requirement of a tolerance on food commodities.
EPA Safer Choice: a voluntary label and Safer Chemical Ingredients List that requires readily biodegradable, low-toxicity surfactants in certified cleaning products.
USDA BioPreferred Program: federal preferred procurement and the 'USDA Certified Biobased Product' label, based on biobased carbon content measured under ASTM D6866.
Modernization of Cosmetics Regulation Act of 2022 (MoCRA): requires facility registration, product listing, safety substantiation and adverse-event reporting for cosmetics containing biosurfactants sold in the United States.
Canada: new substances are notified under the New Substances Notification Regulations of the Canadian Environmental Protection Act, 1999.
Asia Pacific
China – MEE Order No. 12: the Measures for Environmental Management Registration of New Chemical Substances, in force since January 2021, require registration of substances not listed on the Inventory of Existing Chemical Substances in China (IECSC), with regular, simplified and record-filing routes by volume.
Japan – Chemical Substances Control Law (CSCL): jointly administered by METI, MHLW and MOE with technical support from NITE, it requires notification before a new substance is manufactured or imported, with low-volume and small-volume routes.
South Korea – K-REACH: from 1 January 2025 the registration threshold for new substances was raised to one tonne per year, with notification below that level.
India – BioE3 Policy (2024): the Biotechnology for Economy, Environment and Employment policy names high-value bio-based chemicals as a priority theme and funds biomanufacturing hubs and biofoundries through the Department of Biotechnology.
Latin America and Middle East & Africa
Brazil – ANVISA RDC 752/2022: sets classification, labelling and notification or registration requirements for personal hygiene products, cosmetics and perfumes, including those formulated with biosurfactants.
Saudi Arabia: detergents are covered by a Saudi Standards, Metrology and Quality Organization (SASO) technical regulation, and cosmetics are regulated by the Saudi Food and Drug Authority (SFDA).
International Standards
OECD Test Guideline 301 (Ready Biodegradability): the internationally accepted set of 28-day tests that underpins 'readily biodegradable' claims and is referenced by detergent regulations and eco-labels worldwide.
ISO 16128: guidelines for calculating natural and natural-origin indices of cosmetic ingredients and products, widely used to support natural-origin claims for biosurfactants.
ASTM D6866: standard method for determining the biobased carbon content of products by radiocarbon analysis.
Jan 2022: Evonik Industries; Expansion / Agreement; Announced a triple-digit million-euro investment in the first industrial-scale rhamnolipid plant at Slovenská Ľupča, Slovakia, and a long-term supply agreement with Unilever.
Jan 2022: Locus Fermentation Solutions / Dow; Partnership; Dow signed an exclusive agreement to sell Locus Performance Ingredients' sophorolipids globally in home and personal care.
Mar 2022: Evonik Industries; Product Launch; Launched REWOFERM RL 100, a rhamnolipid for laundry, hard-surface, vehicle care and food and beverage cleaning.
Mar 2022: Sasol / Holiferm; Partnership; Sasol agreed to take most of the sophorolipid output of Holiferm's UK plant and to fund Holiferm's research and development.
Jun 2022: Solvay (now Syensqo); Product Launch; Launched the Mirasoft SL L60 and A60 sophorolipid biosurfactants for personal care.
Jun 2022: Evonik Industries; Expansion; Started construction of the rhamnolipid plant in Slovakia.
Aug 2022: AGAE Technologies; Technology; Reported successful operation of its rhamnolipid pilot plants and filed a provisional patent on fermentation and foam control.
Jan 2023: Sasol / Holiferm; Partnership; Extended their collaboration to the production and marketing of rhamnolipids and mannosylerythritol lipids.
Feb 2023: Holiferm; Expansion; Opened its first commercial sophorolipid plant at Wallasey, UK, with about 1,100 tonnes per year of capacity.
Apr 2023: Locus Fermentation Solutions; Investment; Secured a USD 117 million IP-backed loan to expand biosurfactant manufacturing.
Jul 2023: Locus Fermentation Solutions; Expansion; Opened two new biomanufacturing facilities in Solon, Ohio, tripling production capacity.
Oct 2023: Sasol; Product Launch; Introduced the CARINEX (personal care) and LIVINEX (home care and I&I) biosurfactant brands, starting with sophorolipids.
Dec 2023: Holiferm; Investment; Raised GBP 18.5 million to expand Wallasey capacity to 3,500 tonnes per year.
May 2024: Evonik Industries; Expansion; Inaugurated the industrial-scale rhamnolipid plant in Slovenská Ľupča, Slovakia, after first production in January 2024.
Oct 2024: Allied Carbon Solutions; Investment; Raised JPY 550 million in a Series C round to expand production and sales channels.
Oct 2024: Locus Fermentation Solutions; Regulatory Approval; Received U.S. EPA approval for commercial-volume biosurfactant production under an expanded TSCA registration.
Feb 2025: AGAE Technologies; Expansion; Began industrial rhamnolipid production at a full-scale plant in Asia with capacity of more than 1,000 tonnes per year.
Dec 2025: Stepan Company; Divestment; Sold its Lake Providence, Louisiana, manufacturing assets, the site of its fermentation plant, as part of footprint optimisation.
Dec 2025: Locus Fermentation Solutions; Investment; Raised USD 20 million through a convertible note, bringing 2025 growth capital to more than USD 40 million.
May 2026: Syensqo; Strategic Review; Launched a strategic review of its Performance & Care segment, which includes the Mirasoft biosurfactant range.
Political
National bioeconomy strategies, such as the EU Bioeconomy Strategy (November 2025), China's 14th Five-Year Bioeconomy Development Plan and India's BioE3 policy (2024), prioritise domestic biomanufacturing.
In the United States, Executive Order 14081 on biotechnology and biomanufacturing (2022) was revoked in March 2025, leaving the USDA BioPreferred programme and Department of Energy research funding as the main federal support for bio-based products.
Trade policy and tariffs on chemicals and agricultural feedstocks influence the cost competitiveness of imported biosurfactants.
Public research funding for industrial biotechnology, for example under the EU's Circular Bio-based Europe Joint Undertaking, supports scale-up.
Economic
Biosurfactants carry a price premium over conventional surfactants, which ties adoption to consumer willingness to pay for sustainable products.
Feedstock (sugar and vegetable oil) and energy price volatility affect fermentation economics.
Upstream oil and gas investment cycles determine demand in oilfield applications.
Social
Consumer preference for natural, mild and environmentally friendly household and personal care products is rising, particularly among younger consumers.
Growing awareness of microplastics and water pollution increases scrutiny of ingredient lists.
Rural and farmer acceptance of biological inputs is improving in major agricultural economies.
Technological
Synthetic biology and strain engineering are raising titres and enabling non-pathogenic production hosts.
Improved downstream processing, such as membrane separation and in-situ product recovery, is lowering purification costs.
AI-assisted bioprocess optimisation and digital twins are shortening scale-up timelines.
Environmental
Biosurfactants are readily biodegradable, have low aquatic toxicity and are derived from renewable carbon, which supports decarbonisation targets.
Sourcing feedstocks such as palm oil raises deforestation concerns, pushing producers towards certified or alternative feedstocks.
Fermentation energy and water use must be managed to deliver credible life-cycle benefits.
Legal
Chemical registration (REACH, TSCA, China MEE new substance notification, K-REACH) is mandatory before commercial sale.
Anti-greenwashing rules in the EU and consumer-protection guidance elsewhere require verified environmental claims.
Intellectual property on strains and processes is extensive, and freedom-to-operate is a key consideration for entrants.
Profiles of 31 companies operating in the Biosurfactant Market market, including revenue, employee count, and market positioning where available.
Showing 31 of 31 companies
Kaneka is a mid-cap Japanese diversified chemical company. Over the past decade it has been reshaping itself from a commodity-heavy vinyls, foams and fibres producer into what management calls a "Life Focus" solutions company. FY2026 sales were a record ¥811.6bn. They are spread across four reportable units: - Material Solutions (PVC, modifiers, MS polymer, the biodegradable polymer Green Planet™) - Quality of Life Solutions (polyimide films, PV, foams, modacrylic fibres) - Health Care Solutions (blood-purification devices, catheters, neuro-coils, pharma CDMO) - Nutrition Solutions (Kaneka Ubiquinol™, probiotics, margarine/yeast/dairy) Kaneka is a global leader in several niche chemistries: MBS/acrylic impact modifiers, silyl-terminated polyether (MS Polymer™), reduced coenzyme Q10, and modacrylic hair fibre. Profitability is structurally low, with a 4.1% operating margin in FY2026 and a 6.4% ROE. The stock traded at a P/B of about 0.7x in September 2026. Management's 2026 plan targets ¥68bn operating income and 10% ROE by FY2029 (Kaneka "FY2028"). It relies on Medical, E&I and supplement growth, plus aggressive capital-efficiency measures. --- ### What Kaneka does Kaneka makes and sells a broad portfolio of chemical, materials, medical, pharmaceutical and food products. It organises them into ten "Solutions Vehicles" (SVs), grouped into four "Solutions Units" (SUs), which are the reportable segments. Per the FY2026 Tanshin segment note, each SU sets a single global strategy and runs Japanese and overseas subsidiaries as one business. **Company's own description (paraphrased from the FY2026 Tanshin segment note):** **Material SU:** supplies high-performance materials for social infrastructure and lighter, more fuel-efficient mobility, plus advanced materials such as biodegradable polymers that serve environmental goals. **Quality of Life SU:** supplies materials and services for energy saving and smart housing and infrastructure, and serves the IoT/AI information economy. **Health Care SU:** combines devices and pharmaceuticals for medicine, health and nursing care. It is building businesses in biopharmaceuticals and regenerative/cell medicine. **Nutrition SU:** supplies distinctive food materials and supplements for diverse diets and health. It also supports agriculture, livestock and fisheries production. **Corporate purpose framing (Three-Year Initiatives 2026).** The corporate purpose is "KANEKA thinks 'Wellness First'". Its supporting pillars are Life Focus Management, Human-Driven Management, R2B+P ("Research to Business + Production") and "Think Global, Act Local". Management defines "life science" broadly. It covers biomanufacturing (Green Planet™, genome editing, fermentation), biopharma, regenerative medicine, supplements, organic dairy, PV and medical devices — all presented as serving "life on Earth". ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Almost entirely product sales (B2B materials, devices, ingredients, foods). Contract manufacturing (CDMO) revenue sits within Pharma. Kaneka does not disclose any subscription or licensing revenue line; licensing income is not separately reported | | Product vs. service mix | Not disclosed. Kaneka's independent assessment is that product sales are more than 95% of revenue; services are limited to construction-method/PV installation-related services in QOL and CDMO services in Pharma | | Value-chain position | Mid-stream: intermediates, specialty polymers and additives. Downstream: finished medical devices, PV modules, consumer-facing supplements and dairy products. Upstream exposure through chlor-alkali/PVC (naphtha, salt, power) | | Customer types | Industrial compounders and converters (PVC, adhesives/sealants, automotive), electronics makers (FPC/smartphone, TV), housing builders, hospitals and distributors (medical devices), pharma companies (CDMO/API), supplement brands, food manufacturers and bakeries, agricultural users | | End-markets | Construction and housing; automotive and mobility; electronics/ICT (smartphones, AI-related high-frequency); renewable energy; healthcare (cardiology, nephrology/apheresis, neurovascular, GI endoscopy); pharma; dietary supplements; bakery and food; agriculture | | Geographic mix (FY2026) | Japan 55.2%, Asia 20.1%, Europe 10.3%, North America 9.2%, Other 5.2% (FY2026 Tanshin) | ### "Leading-edge" vs "Foundation" portfolio lens Management splits the portfolio into two groups (Three-Year Initiatives 2026): **Leading-edge businesses:** Modified Silicone polymers (MS), E&I Technology, PV & Energy management, Medical, Pharma, and Supplemental Nutrition. **Foundation businesses:** Vinyls & Chlor-Alkali, Modifiers (MOD), Foam & Residential Techs, Performance Fibers, and Foods & Agris. Leading-edge businesses supplied 53% of operating income in FY2026, up from 48% in FY2025. The target is 56% in FY2027 and 62% by FY2029. The 2026 plan also puts Green Planet™ and genome editing in the life-science growth pool. ### Independent characterisation Kaneka is best understood as a portfolio of ten mid-sized niche businesses sitting on a cyclical commodity base. About 40% of revenue (Material SU) is exposed to Asian PVC pricing and Western construction demand. That base has driven most of the earnings volatility seen in FY2026. The value-creation engine lies elsewhere: **Medical devices:** the Health Care SU earned a 17.9% segment margin in FY2026. **E&I polyimide films:** these benefit from AI-driven high-frequency demand. **Global ubiquinol franchise:** The central investment question is whether these businesses can scale fast enough to lift group margins from about 4% toward the 7.3% FY2029 target. A secondary question is whether that can happen before the corporate cost burden absorbs the gains: unallocated corporate expenses (mainly basic R&D) were ¥39.1bn in FY2026, larger than total group operating income.
Company Headquarters: Illinois, US Founded: 1932 Workforce: ~2,250 Company Working: Stepan Company (Stepan) is engaged in the manufacturing and sale of specialty and intermediate chemicals. It operates through the segments, namely surfactants, polymers, and specialty products. Surfactants segment offers oilfield biocides along with a wide range of surfactant chemicals such as anionic, cationic, nonionic, and amphoteric surfactants. The polymers segment produces polyester polyols and phthalic anhydride. The specialty products are chemicals used in food, flavoring, nutritional supplement, and pharmaceutical applications.
Sasol is South Africa's largest integrated energy and chemicals producer and the world's leading commercial operator of Fischer-Tropsch coal-to-liquids and gas-to-liquids technology. Its Southern African value chain begins with captive coal mines and Mozambican natural gas. These feed the Secunda synthetic fuels and chemicals complex and the Sasolburg chemicals operations. The chain extends through the Natref crude refinery to wholesale, commercial and retail fuel channels, and it anchors a domestic polymers, solvents and specialty chemicals business. International Chemicals (the Lake Charles complex in the United States plus sites in Germany, Italy and China) adds alcohols, surfactants, alumina, waxes and olefins. Since 2024 CEO Simon Baloyi has run a "reset". Its main elements are: restoring Secunda volumes and coal quality, cutting cost and capex, closing loss-making international units, and deleveraging towards US$3bn of net debt before dividends resume. FY2026 delivered adjusted EBITDA up 17% to R60.7bn and net debt of US$3.3bn. The equity nevertheless remains a geared exposure to oil, the rand and chemical cycles, overlaid by heavy carbon-transition risk. --- ### Company self-description In its FY2026 materials Sasol describes itself as a global energy and chemicals company. It says it applies its knowledge and technology inside large, world-scale plants, and that it sources, produces and markets a broad range of products to create value for stakeholders [AIA26]. Its product overview lists: diesel, petrol, naphtha, jet fuel, LPG, olefins, alcohols, polymers, solvents, surfactants, co-monomers, ammonia, methanol, crude tar acids, sulphur, illuminating paraffin, bitumen and fuel oil, plus further derivatives [R26 web page]. ### Independent characterisation Sasol is two businesses joined by a balance sheet. 1. **Southern Africa Energy and Chemicals (SA E&C).** This is a vertically integrated, coal- and gas-based Fischer-Tropsch value chain. - **Inputs:** 28.4 mm tons of saleable coal (FY2026) and 114.0 bscf of Mozambican natural gas. - **Conversion:** the Secunda Operations (SO) complex produced 7.26 mm tons in FY2026, of which fuels were 3.63 mm t and chemicals 3.00 mm t. Natref, Sasol's 63.64%-owned crude refinery, produced 25.8 mm bbl in FY2026. - **Sales:** 57.5 mm bbl of liquid fuels through three channels (Mobility/retail 10.5, Commercial 28.0, Wholesale 19.0 mm bbl), and 3,542 kt of Chemicals Africa external sales. - In FY2026 the segment generated R189.9bn of external turnover (70% of group) and R46.8bn of adjusted EBITDA (77% of group) [AIA26]. 2. **International Chemicals (IC).** This comprises Chemicals America (the Lake Charles, Louisiana complex: ethane cracker, Ziegler alcohols, alumina, ethylene oxide/glycol, tetramerisation, co-monomers) and Chemicals Eurasia (Germany, Italy, China: essential care chemicals, alcohols, linear alkylbenzene, paraffins, high-purity alumina). IC generated R82.2bn of external turnover (30%) and R10.2bn of adjusted EBITDA (US$604m; 12% margin) in FY2026 [AIA26]. ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue type | Almost entirely product sales (fuels, gas, chemicals). Minor other income comes from technology licence fees, rental income (including Richards Bay Coal Terminal capacity leasing), emission grants and insurance proceeds. No material subscription revenue | [AIA26] "Other income" note | | Product vs service vs licensing mix | Product ≈ 98–99%+. Licensing and services are not separately disclosed as revenue; they sit within other income (R4.1bn total other income in FY2026, all types) | [AIA26] | | Pricing | SA fuels are priced off the regulated Basic Fuel Price (import-parity) formula. SA piped gas is priced under NERSA maximum-gas-price regulation. Chemicals follow global commodity benchmarks (Sasol says it is not a price-setter for most of its chemicals portfolio) | [AIA26] key sensitivities; [20F26] | | Value-chain position | Upstream (coal mining, gas production) → midstream (FT synthesis, gasification, refining, cracking) → downstream (fuel retail, chemical derivatives) | [AIA26] | | Customer types | Fuel retailers and franchisees; commercial and industrial fuel buyers (mining, agriculture, transport, aviation including O.R. Tambo International Airport jet fuel supply); oil-company wholesale customers; industrial gas users; chemical converters and formulators (packaging, detergents, personal care, coatings, pharmaceuticals, catalysts, explosives) | [AIA26]; [NEWS] | | End-markets | Transport fuels and aviation; mining and explosives; agriculture (fertilisers); packaging and plastics (polyethylene, polypropylene, PVC); home and personal care (surfactants, alcohols); coatings, inks and adhesives (solvents); catalysts, ceramics and battery/advanced materials (alumina); energy and power | [20F26]; company product catalogue | ### Key FY2026 operating scale [AIA26] | Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Saleable coal production (mm t) | 30.2 | 28.2 | 28.4 | | Mozambique natural gas production (bscf) | 120.8 | 122.2 | 114.0 | | Secunda Operations production (kt) | 6990 | 6721 | 7260 | | Natref production (mm bbl) | 17.8 | 14.7 | 25.8 | | ORYX GTL production, Sasol share basis (mm bbl) | 2.9 | 5.0 | 3.0 | | Liquid fuel sales (mm bbl) | 51.7 | 50.9 | 57.5 | | Chemicals Africa external sales (kt) | 3515 | 3375 | 3542 | | Chemicals America external sales (kt) | 1764 | 1592 | 1904 | | Chemicals Eurasia external sales (kt) | 1026 | 990 | 942 |
Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
3 interactive charts drawn from the Biosurfactant Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Biosurfactant Market By Application
Global Biosurfactant Market By Product Type
Global Biosurfactant Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
